The systemic immune-inflammation index was non-linear associated with all-cause mortality in individuals with nonalcoholic fatty liver disease

References

• Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48(4):1–11.
   PubMed Web of Science ®Google Scholar
• Huby T, Gautier EL. Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol. 2022;22:429–443.
   PubMed Web of Science ®Google Scholar
• Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377(21):2063–2072.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922.
   PubMed Web of Science ®Google Scholar
• Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822–1832.
   PubMed Web of Science ®Google Scholar
• Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol. 2004;34(1):9–19.
   PubMed Web of Science ®Google Scholar
• Ribeiro PS, Cortez-Pinto H, Solá S, et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol. 2004;99(9):1708–1717.
   PubMed Web of Science ®Google Scholar
• Petrescu M, Vlaicu SI, Ciumărnean L, et al. Chronic inflammation-A link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue. Medicina. 2022;58(5):641.
   PubMedGoogle Scholar
• Heymann F, Tacke F. Immunology in the liver–from homeostasis to disease. Nat Rev Gastroenterol Hepatol. 2016;13(2):88–110.
   PubMed Web of Science ®Google Scholar
• Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177.
   PubMed Web of Science ®Google Scholar
• Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol. 2020;17(2):81–92.
   PubMed Web of Science ®Google Scholar
• Yang R, Chang Q, Meng X, et al. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer. 2018;9(18):3295–3302.
   PubMed Web of Science ®Google Scholar
• Song Y, Guo W, Li Z, et al. Systemic immune-inflammation index is associated with hepatic steatosis: evidence from NHANES 2015–2018. Front Immunol. 2022;13:1058779.
   PubMed Web of Science ®Google Scholar
• Aziz MH, Sideras K, Aziz NA, et al. The systemic-immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels: a retrospective multicenter cohort study. Ann Surg. 2019;270(1):139–146.
   PubMed Web of Science ®Google Scholar
• Qin Z, Li H, Wang L, et al. Systemic immune-inflammation index is associated with increased urinary albumin excretion: a population-based study. Front Immunol. 2022;13:863640.
   PubMed Web of Science ®Google Scholar
• Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020;50(5):e13230.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen Z. Higher systemic immune-inflammation index is associated with higher likelihood of peripheral arterial disease. Ann Vasc Surg. 2022;84:322–326.
   PubMed Web of Science ®Google Scholar
• Tosu AR, Biter H. Association of systemic immune-inflammation index (SII) with presence of isolated coronary artery ectasia. Arch Med Sci Atheroscler Dis. 2021;6:e152–e157.
   PubMedGoogle Scholar
• He L, Xie X, Xue J, et al. Association of the systemic immune-inflammation index with all-cause mortality in patients with arteriosclerotic cardiovascular disease. Front Cardiovasc Med. 2022;9:952953.
   PubMed Web of Science ®Google Scholar
• Guo W, Song Y, Sun Y, et al. Systemic immune-inflammation index is associated with diabetic kidney disease in type 2 diabetes mellitus patients: evidence from NHANES 2011-2018. Front Endocrinol. 2022;13:1071465.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou D, Dai Z, et al. Association between systemic immune-inflammation index and diabetic depression. Clin Intervention Aging. 2021;16:97–105.
   PubMed Web of Science ®Google Scholar
• Di X, Liu S, Xiang L, et al. Association between the systemic immune-inflammation index and kidney stone: a cross-sectional study of NHANES 2007–2018. Front Immunol. 2023;14:1116224.
   PubMed Web of Science ®Google Scholar
• Mahemuti N, Jing X, Zhang N, et al. Association between systemic immunity-inflammation index and hyperlipidemia: a population-based study from the NHANES (2015–2020). Nutrients. 2023;15(5):1177.
   PubMed Web of Science ®Google Scholar
• Xiao S, Wang Z, Zuo R, et al. Association of systemic immune inflammation index with all-cause, cardiovascular disease, and cancer-related mortality in patients with cardiovascular disease: a cross-sectional study. J Inflamm Res. 2023;16:941–961.
   PubMed Web of Science ®Google Scholar
• Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127(1):55–64.
   PubMed Web of Science ®Google Scholar
• Qin G, Ma J, Huang Q, et al. Isoquercetin improves hepatic lipid accumulation by activating AMPK pathway and suppressing TGF-β signaling on an HFD-Induced nonalcoholic fatty liver disease rat model. Int J Mol Sci. 2018;19(12):4126.
   PubMed Web of Science ®Google Scholar
• Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20(23):6212–6222.
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–508.
   PubMedGoogle Scholar
• Meffert PJ, Baumeister SE, Lerch MM, et al. Development, external validation, and comparative assessment of a new diagnostic score for hepatic steatosis. Am J Gastroenterol. 2014;109(9):1404–1414.
   PubMed Web of Science ®Google Scholar
• Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–1112.
   PubMed Web of Science ®Google Scholar
• VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med. 2017;167(4):268–274.
   PubMed Web of Science ®Google Scholar
• Zhu JZ, Dai YN, Wang YM, et al. Prevalence of nonalcoholic fatty liver disease and economy. Dig Dis Sci. 2015;60(11):3194–3202.
   PubMed Web of Science ®Google Scholar
• Schuster S, Cabrera D, Arrese M, et al. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349–364.
   PubMed Web of Science ®Google Scholar
• Tilg H, Adolph TE, Dudek M, et al. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab. 2021;3(12):1596–1607.
   PubMedGoogle Scholar
• Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarction. Am J Cardiol. 2010;106(4):470–476.
   PubMed Web of Science ®Google Scholar
• Kurtul A, Ornek E. Platelet to lymphocyte ratio in cardiovascular diseases: a systematic review. Angiology. 2019;70(9):802–818.
   PubMed Web of Science ®Google Scholar
• Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272.
   PubMed Web of Science ®Google Scholar
• Rensen SS, Slaats Y, Nijhuis J, et al. Increased hepatic myeloperoxidase activity in obese subjects with nonalcoholic steatohepatitis. Am J Pathol. 2009;175(4):1473–1482.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Xu MJ, Cai Y, et al. Neutrophil-hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis. Cell Mol Gastroenterol Hepatol. 2018;5(3):399–413.
   PubMed Web of Science ®Google Scholar
• Wang X, Seo W, Park SH, et al. MicroRNA-223 restricts liver fibrosis by inhibiting the TAZ-IHH-GLI2 and PDGF signaling pathways via the crosstalk of multiple liver cell types. Int J Biol Sci. 2021;17(4):1153–1167.
   PubMed Web of Science ®Google Scholar
• Shah AD, Denaxas S, Nicholas O, et al. Neutrophil counts and initial presentation of 12 cardiovascular diseases: a CALIBER cohort study. J Am Coll Cardiol. 2017;69(9):1160–1169.
   PubMed Web of Science ®Google Scholar
• He S, Lei W, Li J, et al. Relation of platelet parameters with incident cardiovascular disease (the Dongfeng-Tongji cohort study). Am J Cardiol. 2019;123(2):239–248.
   PubMed Web of Science ®Google Scholar
• Ballerini P, Contursi A, Bruno A, et al. Inflammation and cancer: from the development of personalized indicators to novel therapeutic strategies. Front Pharmacol. 2022;13:838079.
   PubMed Web of Science ®Google Scholar
• Miele L, Alberelli MA, Martini M, et al. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Transl Res. 2021;231:24–38.
   PubMed Web of Science ®Google Scholar
• Simon TG, Henson J, Osganian S, et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019;17(13):2776–2784.
   PubMed Web of Science ®Google Scholar
• Carpino G, Del Ben M, Pastori D, et al. Increased liver localization of lipopolysaccharides in human and experimental NAFLD. Hepatology. 2020;72(2):470–485.
   PubMed Web of Science ®Google Scholar
• Chen Y, Tian Z. Roles of hepatic innate and innate-like lymphocytes in nonalcoholic steatohepatitis. Front Immunol. 2020;11:1500.
   PubMed Web of Science ®Google Scholar
• Kawanaka M, Nishino K, Ishii K, et al. Combination of type IV collagen 7S, albumin concentrations, and platelet count predicts prognosis of non-alcoholic fatty liver disease. World J Hepatol. 2021;13(5):571–583.
   PubMed Web of Science ®Google Scholar
• Pasalic L, Wang SS, Chen VM. Platelets as biomarkers of coronary artery disease. Semin Thromb Hemost. 2016;42(3):223–233.
   PubMed Web of Science ®Google Scholar
• Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115(12):3378–3384.
   PubMed Web of Science ®Google Scholar
• Núñez J, Miñana G, Bodí V, et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem. 2011;18(21):3226–3233.
   PubMed Web of Science ®Google Scholar
• Darbandi M, Hamzeh B, Ayenepour A, et al. Anti-inflammatory diet consumption reduced fatty liver indices. Sci Rep. 2021;11(1):22601.
   PubMed Web of Science ®Google Scholar